



**SMALL MOMENT. BIG DIFFERENCE.**


Last month Henry had a TBI.

Today he is successful in his job again.



# Big Problem with cognitive impairment after TBI – What to do?

The most common neurocognitive consequences<sup>1</sup> of TBI at all levels of severity are disturbances of



- These problems **may cause additional disturbances** (e.g. in communication)
- Cognitive impairments create **big socio-economic burdens** for patients and family members<sup>2</sup>

**Treatment of such consequences is essential!**

# Take life into your own hands again!

- Improvement of memory and concentration impairment after TBI
- Faster reintegration into worklife
- Sound decision making



Figure: Single cognitive outcomes, MW, Day 90, PP

Large inferiority = 0,29; Medium inferiority = 0,36; Small inferiority = 0,44; Equality = 0,50;  
Small superiority = 0,56; Medium superiority = 0,64; Large superiority = 0,71

- All 3 cognition scales are **statistically significant**
- Scales show **large-sized superiority**
- **Even on day 30** already large treatment effects in Digit Span Backward test

# Treat TBI patients with Cerebrolysin® as soon as possible!

## The effective treatment after TBI

- Early treatment effects
- Significantly reduced depression
- Improvement of memory and concentration

Disorder	Daily dosage	Initiation of treatment	Duration of treatment
Traumatic brain injury	20 - 50 ml	as soon as possible	7 - 30 days

**Title:** Efficacy and safety of Cerebrolysin® in Neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial

**Patients:** 80 Cerebrolysin® group + 59 Placebo group = 139 patient in total

**Treatment:** Treatment Cycle 1 = Day 1 - 10 : 50 ml/day  
Treatment Cycle 2 = Day 31 - 40 : 10 ml/day  
Treatment Cycle 3 = Day 61 - 70 : 10 ml/day

1 <https://www.ncbi.nlm.nih.gov/pubmed/11734103>

2 Muresanu, Dafin F., et al., „Efficacy and safety of cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial.“ Neurological Sciences: 1-11